Ocular Rises as Needham Issues New Buy on Lead Candidate
Morgan Stanley Maintains Overweight on BioNTech, Lowers Price Target to $139
Genmab Upgraded to Outperform at William Blair
Gilead Sciences To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday
The Analyst Verdict: Gilead Sciences In The Eyes Of 14 Experts
Top 3 Health Care Stocks That May Keep You Up At Night In Q1